The trademark application was filed by Otsuka Pharmaceutical Co., Ltd., a corporation established under the laws of Japan (the "Applicant"). The application was published for oppositions on October 10, 2024, and still open for oppositions.
The application was filed in English (Spanish was selected as the second language).